Special Issue

Innovative Technologies to Treat Diseases of the Back of the Eye

Message from the Guest Editors

Delivering drugs targeted for posterior segment diseases of the eye in a safe, patient-friendly, and controlled manner has long been the focus of drug delivery researchers. With an aim to develop smart materials capable of the controlled release of ophthalmic drugs relevant in the treatment and management of back of the eye diseases, such research hopes to meet the challenges associated with the global rise in such diseases. Much of the focus has worked towards the development of both nanomaterial delivery carriers and extended-release platforms, such as nano- and micro-devices, implants and contact lenses, as effective means to bypass the ocular barriers and deliver drug efficiently to the posterior segment of the eye. All these innovative technologies are emerging as efficient therapeutic tools in the personalized treatment of back of the eye diseases. The development of animal models of posterior segment diseases is also a critical issue as most of these pathologies are chronic and multifactorial.

Guest Editors

Prof. Dr. Rocio Herrero-Vanrell

Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Madrid, Spain

Dr. Laurence Fitzhenry

Ocular Therapeutics Research Group, Pharmaceutical and Molecular Biotechnology Research Centre (PMBRC), Department of Science, Waterford Institute of Technology, Waterford, Ireland

Deadline for manuscript submissions

closed (31 May 2022)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/55168

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

